CEO John Jacobs was paid $8,856,015 in fiscal year 2025, ↑ up 74.1% from fiscal year 2024, the 61st percentile of its disclosed peer group (SEC filing 0001628280-26-027328 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$8,856,015 ↑ John Jacobs total, FY2025 | 61st CEO pay percentile vs peers | 52:1 CEO-to-median pay ratio | 50.65% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
NVAX's next annual pay disclosure, estimated April 25, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Jacobs | $792,917 | $0 | $3,545,435 | $3,763,292 | $640,331 | $0 | $114,040 | $8,856,015 |
| President and CEO | ||||||||
| Elaine O'Hara | 561,080 | 0 | 1,330,030 | 1,411,235 | 288,143 | 0 | 97,788 | 3,688,276 |
| EVP, Chief Strategy Officer | ||||||||
| James Kelly | 572,886 | 0 | 1,019,165 | 1,082,782 | 297,362 | 0 | 14,033 | 2,986,228 |
| EVP, Chief Financial Officer and Treasurer | ||||||||
| Mark Casey | 577,831 | 0 | 885,375 | 940,823 | 289,660 | 0 | 116,764 | 2,810,453 |
| EVP, Chief Legal Officer and Corporate Secretary | ||||||||
| Ruxandra Draghia-Akli | 600,000 | 0 | 629,600 | 668,040 | 290,250 | 0 | 115,490 | 2,303,380 |
| Former EVP, Head of Research & Development | ||||||||
| John Trizzino | 310,016 | 0 | 368,624 | 209,724 | 0 | 0 | 821,586 | 1,709,950 |
| Former President and Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Jacobs | $8,856,015 | $5,087,461 | $7,301,009 | ↑ +3,768,554 |
| Elaine O'Hara | 3,688,276 | 1,638,116 | — | ↑ +2,050,160 |
| James Kelly | 2,986,228 | 1,829,489 | 1,503,833 | ↑ +1,156,739 |
| Mark Casey | 2,810,453 | 1,062,334 | 1,534,587 | ↑ +1,748,119 |
| Ruxandra Draghia-Akli | 2,303,380 | — | — | — |
| John Trizzino | 1,709,950 | 1,633,417 | 1,877,883 | ↑ +76,533 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Novavax's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper NVAX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name NVAX as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Charles W. Newton | Independent Director | $491,949 |
| David Mott | Chair of the Board | $365,591 |
| Gregg H. Alton, J.D | Independent Director | $355,091 |
| James F. Young, Ph.D | Former director (through FY2025) | $58,750 |
| John W. Shiver, Ph.D | Independent Director | $516,545 |
| Margaret G. McGlynn, R. Ph | Independent Director | $402,278 |
| Rachel K. King | Independent Director | $353,091 |
| Richard H. Douglas, Ph.D | Independent Director | $364,462 |
| Richard J. Rodgers | Independent Director | $375,449 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| John W. Shiver | Director | 2026-06-18 | A | 21,270 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret G. McGlynn | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles W. Newton | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles W. Newton | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John W. Shiver | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg H. Alton | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg H. Alton | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret G. McGlynn | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rachel K. King | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rachel K. King | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Rodgers | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Rodgers | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-06-20 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-06-20 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Margaret G. McGlynn | Director | 2026-06-20 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret G. McGlynn | Director | 2026-06-20 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-20 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-20 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Rachel K. King | Director | 2026-06-20 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rachel K. King | Director | 2026-06-20 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Richard J. Rodgers | Director | 2026-06-20 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Rodgers | Director | 2026-06-20 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Gregg H. Alton | Director | 2026-06-20 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg H. Alton | Director | 2026-06-20 | A | 18,880 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Ruxandra Draghia-Akli | RSU | 2025-03-03 | — | — | 80,000 | — | $629,600 |
| Ruxandra Draghia-Akli | OPTION | 2025-03-03 | — | — | 120,000 | — | 668,040 |
| John Jacobs | RSU | 2025-03-03 | — | — | 450,500 | — | 3,545,435 |
| John Jacobs | OPTION | 2025-03-03 | — | — | 676,000 | — | 3,763,292 |
| James Kelly | OPTION | 2025-03-03 | — | — | 194,500 | — | 1,082,782 |
| Elaine O Hara | RSU | 2025-03-03 | — | — | 169,000 | — | 1,330,030 |
| Mark Casey | RSU | 2025-03-03 | — | — | 112,500 | — | 885,375 |
| James Kelly | RSU | 2025-03-03 | — | — | 129,500 | — | 1,019,165 |
| Mark Casey | OPTION | 2025-03-03 | — | — | 169,000 | — | 940,823 |
| Elaine O Hara | OPTION | 2025-03-03 | — | — | 253,500 | — | 1,411,235 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Ruxandra Draghia-Akli | $629,600 | $0 | $668,040 | 0.0% |
| John Jacobs | 3,545,435 | 0 | 3,763,292 | 0.0% |
| James Kelly | 1,019,165 | 0 | 1,082,782 | 0.0% |
| Elaine O Hara | 1,330,030 | 0 | 1,411,235 | 0.0% |
| Mark Casey | 885,375 | 0 | 940,823 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| John Jacobs | RSU | 450,500 | — | $3,027,360 |
| Elaine O'Hara | RSU | 169,000 | — | 1,135,680 |
| John Jacobs | RSU | 166,666 | — | 1,119,996 |
| James Kelly | RSU | 129,500 | — | 870,240 |
| James Kelly | RSU | 117,333 | — | 788,478 |
| Mark Casey | RSU | 112,500 | — | 756,000 |
| John Trizzino | RSU | 96,000 | — | 645,120 |
| John Jacobs | RSU | 83,197 | — | 559,084 |
| Elaine O'Hara | RSU | 80,000 | — | 537,600 |
| Ruxandra Draghia-Akli | RSU | 80,000 | — | 537,600 |
| Mark Casey | RSU | 41,899 | — | 281,561 |
| John Trizzino | RSU | 28,890 | — | 194,141 |
| Ruxandra Draghia-Akli | RSU | 28,513 | — | 191,607 |
| Elaine O'Hara | RSU | 19,600 | — | 131,712 |
| James Kelly | RSU | 12,223 | — | 82,139 |
| Mark Casey | RSU | 8,000 | — | 53,760 |
| John Jacobs | Option | 281,251 | 5.39 | — |
| John Jacobs | Option | 676,000 | 7.87 | — |
| James Kelly | Option | 1,297 | 77.77 | — |
| James Kelly | Option | 13,235 | 6.97 | — |
| James Kelly | Option | 194,500 | 7.87 | — |
| James Kelly | Option | 21,219 | 6.86 | — |
| Elaine O'Hara | Option | 253,500 | 7.87 | — |
| Elaine O'Hara | Option | 72,348 | 5.57 | — |
| Mark Casey | Option | 169,000 | 7.87 | — |
| John Trizzino | Option | 1,297 | 77.77 | — |
| John Trizzino | Option | 46,777 | 9.01 | — |
| Ruxandra Draghia-Akli | Option | 120,000 | 7.87 | — |
| CEO STI target (% of salary) | 85% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-18 | 35,779,461 | 34,858,658 | 737,897 | 50.65% | Passed |
| 2025 | 2025-06-20 | 41,390,651 | 15,830,308 | 530,262 | 72.33% | Passed |
| 2024 | 2024-06-13 | 24,187,672 | 8,695,357 | 11,007,350 | 73.56% | Passed |
| 2023 | 2023-07-11 | 15,695,578 | 3,030,052 | 538,435 | 83.82% | Passed |
| 2022 | 2022-06-16 | 19,618,798 | 6,574,169 | 243,539 | 74.9% | Passed |
| 2021 | 2021-06-17 | 31,917,668 | 8,631,639 | 340,263 | 78.71% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-18 | 50.65%a |
| 2025 | 2025-06-20 | 72.33%b |
| 2024 | 2024-06-13 | 73.56%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as shares voting on this matter and accordingly will have no effect on the approval of this Proposal 3.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 52 : 1 |
|---|---|
| CEO total compensation | $8,856,015 |
| Median employee compensation | $169,449 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John W. Shiver, Ph.DIndependent · Compensation | $59,987 | $195,011 | $261,547 | — | — | $516,545 |
| Charles W. NewtonIndependent · Capital Allocation · Audit · Nominating & Corporate Governance · Independent · Newly elected | 45,982 | 190,495 | 255,472 | — | — | 491,949 |
| Margaret G. McGlynn, R. PhIndependent · Nominating & Corporate Governance · Independent · Research & Development | 119,187 | 121,021 | 162,070 | 0 | 0 | 402,278 |
| Richard J. RodgersIndependent · Compensation · Capital Allocation · Audit (Chair) · Independent | 92,358 | 121,021 | 162,070 | 0 | 0 | 375,449 |
| David MottIndependent · Board Chair · Compensation (Chair) · Capital Allocation · Independent · Research & Development | 82,500 | 121,021 | 162,070 | 0 | 0 | 365,591 |
| Richard H. Douglas, Ph.DIndependent · Audit | 81,371 | 121,021 | 162,070 | 0 | 0 | 364,462 |
| Gregg H. Alton, J.DIndependent · Capital Allocation · Audit · Nominating & Corporate Governance · Independent · Compensation | 72,000 | 121,021 | 162,070 | 0 | 0 | 355,091 |
| Rachel K. KingIndependent · Compensation · Nominating & Corporate Governance · Independent | 70,000 | 121,021 | 162,070 | 0 | 0 | 353,091 |
| James F. Young, Ph.DIndependent · Departed during FY | 58,750 | — | — | — | 0 | 58,750 |
| John C. JacobsEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $350,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 12,500 |
| Stock ownership guideline | ck equivalent in value to a multiple of the individual’s salary or, in the case of directors, their annual cash retainer, as follows: |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $682,135 |
| Equity awards (grant-date value) | $1,111,632 |
| All other compensation | $0 |
| Total cost of the board | $1,793,767 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Novavax names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Novavax.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | $1,000,000 | $19,350,145 | $1,650,014 | $1,147,500 | $23,166,223 |
| 2 | Supernus Pharmaceuticals, Inc. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 3 | Corcept Therapeutics Incorporated | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 4 | Insmed Incorporated | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 5 | BioCryst Pharmaceuticals, Inc. | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 6 | Pacira BioSciences, Inc. | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 7 | Crinetics Pharmaceuticals, Inc. | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 8 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 9 | ANI Pharmaceuticals, Inc. | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 10 | Novavax | 2025 | John Jacobs | 792,917 | 3,545,435 | 3,763,292 | 640,331 | 8,856,015 |
| 11 | Amneal Pharmaceuticals Inc. | 2025 | Chirag Patel | 800,000 | 6,974,995 | 0 | 848,000 | 8,691,745 |
| 12 | Amphastar Pharmaceuticals, Inc. | 2025 | Jack Yongfeng Zhang | 950,911 | 3,301,981 | 3,302,024 | 361,000 | 8,309,350 |
| 13 | ACADIA Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 14 | Dynavax Technologies Corporation | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 15 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 16 | Vir Biotechnology, Inc. | 2025 | Marianne De Backer | 950,000 | 2,296,800 | 3,507,360 | 1,002,750 | 7,834,045 |
| 17 | Organogenesis Holdings, Inc. | 2025 | Gary Gillheeney | 979,105 | 2,833,330 | 1,380,017 | 1,536,575 | 6,811,754 |
| 18 | Arvinas, Inc | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 19 | Bicycle | 2025 | Kevin Lee | 862,339 | 1,724,800 | 2,961,297 | 543,642 | 6,341,473 |
| 20 | Beam Therapeutics Inc. | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 21 | Emergent BioSolutions Inc. | 2025 | Joseph Papa | 1,037,385 | 1,638,500 | 1,191,500 | 1,446,640 | 5,321,147 |
| 22 | Intellia Therapeutics, Inc. | 2025 | John Leonard | 708,000 | 2,443,920 | 1,356,320 | 0 | 5,063,899 |
| 23 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 24 | Sana Biotechnology, Inc. | 2025 | Steven Harr | 696,140 | 425,001 | 1,327,500 | 450,369 | 2,903,010 |
| — | PTC Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Novavax | 95% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| ACADIA Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Alkermes plc | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Amneal Pharmaceuticals Inc. | 106% | PSU 65 · RSU 35 | No | Meridian |
| Amphastar Pharmaceuticals, Inc. | not disclosed | Options 50 · RSU 50 | not disclosed | Willis Towers Watson (WTW) |
| ANI Pharmaceuticals, Inc. | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| Arvinas, Inc | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Beam Therapeutics Inc. | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Bicycle | 97% | not disclosed | not disclosed | not disclosed |
| BioCryst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Corcept Therapeutics Incorporated | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Crinetics Pharmaceuticals, Inc. | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Dynavax Technologies Corporation | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Emergent BioSolutions Inc. | 107% | Options 50 · PSU 50 | No | WTW |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Insmed Incorporated | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Intellia Therapeutics, Inc. | 115% | Option 40 · RSU 40 · PSU 20 | Yes — TSR relative to the Nasdaq Biotechnology Index | Alpine |
| Organogenesis Holdings, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Pacira BioSciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| PTC Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Sana Biotechnology, Inc. | 107.5% | not disclosed | not disclosed | Aon plc (Human Capital Solutions practice) |
| Supernus Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| Vir Biotechnology, Inc. | 125% | Options 67 · RSU 33 | not disclosed | Semler Brossy |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, John Jacobs | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Summary Compensation Table”. As printed: 8,856,015. Filing ↗machine: r2 · c24 · span 944385–944394 |
| 2 | Section 01, Elaine O'Hara | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Summary Compensation Table”. As printed: 3,688,276. Filing ↗machine: r10 · c24 · span 959901–959910 |
| 3 | Section 01, James Kelly | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Summary Compensation Table”. As printed: 2,986,228. Filing ↗machine: r6 · c24 · span 952171–952180 |
| 4 | Section 01, Mark Casey | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Summary Compensation Table”. As printed: 2,810,453. Filing ↗machine: r13 · c24 · span 965741–965750 |
| 5 | Section 01, Ruxandra Draghia-Akli | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Summary Compensation Table”. As printed: 2,303,380. Filing ↗machine: r21 · c24 · span 982057–982066 |
| 6 | Section 01, John Trizzino | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Summary Compensation Table”. As printed: 1,709,950. Filing ↗machine: r17 · c24 · span 973879–973888 |
| 7 | Section 03, Ruxandra Draghia-Akli RSU | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t181 · r6 · c1 · span 882597–882603 |
| 8 | Section 03, Ruxandra Draghia-Akli OPTION | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r6 · c1 · span 877991–877998 |
| 9 | Section 03, John Jacobs RSU | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t181 · r2 · c1 · span 880539–880546 |
| 10 | Section 03, John Jacobs OPTION | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r2 · c1 · span 875933–875940 |
| 11 | Section 03, James Kelly OPTION | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r3 · c1 · span 876420–876427 |
| 12 | Section 03, Elaine O Hara RSU | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t200 · r13 · c8 · span 1012633–1012642 |
| 13 | Section 03, Mark Casey RSU | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t181 · r5 · c1 · span 882015–882022 |
| 14 | Section 03, James Kelly RSU | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t181 · r3 · c1 · span 881026–881033 |
| 15 | Section 03, Mark Casey OPTION | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r5 · c1 · span 877409–877416 |
| 16 | Section 03, Elaine O Hara OPTION | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r4 · c1 · span 876906–876913 |
| 17 | Section 07, pay ratio | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “CEO Pay Ratio”. As printed: 52 : 1. Filing ↗machine: t230 · r3 · c1 · span 1235866–1235873 |
| 18 | Section 08, John W. Shiver, Ph.D | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 516,545. Filing ↗machine: span 592030–592150 |
| 19 | Section 08, Charles W. Newton | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 491,949. Filing ↗machine: span 589449–589569 |
| 20 | Section 08, Margaret G. McGlynn, R. Ph | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 402,278. Filing ↗ |
| 21 | Section 08, Richard J. Rodgers | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 375,449. Filing ↗ |
| 22 | Section 08, David Mott | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 365,591. Filing ↗ |
| 23 | Section 08, Richard H. Douglas, Ph.D | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 364,462. Filing ↗machine: span 584480–584600 |
| 24 | Section 08, Gregg H. Alton, J.D | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 355,091. Filing ↗ |
| 25 | Section 08, Rachel K. King | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 353,091. Filing ↗ |
| 26 | Section 08, James F. Young, Ph.D | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 58,750. Filing ↗machine: t106 · r10 · c1 · span 593596–593715 |
| 27 | Section 08, John C. Jacobs | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 28 | Section 02, John W. Shiver 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076923 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Margaret G. McGlynn 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Charles W. Newton 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Charles W. Newton 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, John W. Shiver 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076923 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Gregg H. Alton 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Gregg H. Alton 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, David Mott 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, David Mott 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Margaret G. McGlynn 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Richard Douglas 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076927 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Richard Douglas 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076927 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Rachel K. King 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076928 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Rachel K. King 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076928 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Richard J. Rodgers 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Richard J. Rodgers 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, David Mott 2026-06-20 | Form 4 | 2026-06-23 | 0001104659-26-076925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, David Mott 2026-06-20 | Form 4 | 2026-06-23 | 0001104659-26-076925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Margaret G. McGlynn 2026-06-20 | Form 4 | 2026-06-23 | 0001104659-26-076926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Margaret G. McGlynn 2026-06-20 | Form 4 | 2026-06-23 | 0001104659-26-076926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Richard Douglas 2026-06-20 | Form 4 | 2026-06-23 | 0001104659-26-076927 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Richard Douglas 2026-06-20 | Form 4 | 2026-06-23 | 0001104659-26-076927 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Rachel K. King 2026-06-20 | Form 4 | 2026-06-23 | 0001104659-26-076928 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Rachel K. King 2026-06-20 | Form 4 | 2026-06-23 | 0001104659-26-076928 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Richard J. Rodgers 2026-06-20 | Form 4 | 2026-06-23 | 0001104659-26-076930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Richard J. Rodgers 2026-06-20 | Form 4 | 2026-06-23 | 0001104659-26-076930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Gregg H. Alton 2026-06-20 | Form 4 | 2026-06-23 | 0001104659-26-076924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Gregg H. Alton 2026-06-20 | Form 4 | 2026-06-23 | 0001104659-26-076924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 06, 2026 vote | Form 8-K | 2026-06-23 | 0001104659-26-076648 | Item 5.07 · say-on-pay result. As reported: 50.65% (votes for as printed: 35,779,461). Filing ↗ |
| 57 | Section 06, 2025 vote | Form 8-K | 2025-06-24 | 0001104659-25-061874 | Item 5.07 · say-on-pay result. As reported: 72.33% (votes for as printed: 41,390,651). Filing ↗ |
| 58 | Section 06, 2024 vote | Form 8-K | 2024-06-14 | 0001104659-24-071735 | Item 5.07 · say-on-pay result. As reported: 73.56% (votes for as printed: 24,187,672). Filing ↗ |
| 59 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 60 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 61 | Section 09b board cost (computed) | Computed | — | — | Cash 682,135 + equity 1,111,632 + all other 0 = 1,793,767, summed across the director compensation table rows.machine: formula: Σ = 1,793,767 |
| 62 | Halozyme Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 63 | Supernus Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053111 | CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604 |
| 64 | Corcept Therapeutics Incorporated, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics Incorporated's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 65 | Insmed Incorporated, Section 10b CEO total | DEF 14A | 2026-04-01 | 0001104506-26-000022 | CEO total compensation as printed in Insmed Incorporated's own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563 |
| 66 | BioCryst Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026822 | CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266 |
| 67 | Pacira BioSciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 68 | Crinetics Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001658247-26-000030 | CEO total compensation as printed in Crinetics Pharmaceuticals, Inc.'s own proxy. As printed: 11,628,959. Filing ↗machine: r2 · c48 · span 589450–589460 |
| 69 | Ultragenyx Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 70 | ANI Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001023024-26-000039 | CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. Filing ↗machine: r2 · c48 · span 484144–484154 |
| 71 | Novavax (subject), Section 10b CEO total | DEF 14A | 2026-04-27 | 0001628280-26-027328 | CEO total compensation as printed in Novavax's own proxy. As printed: 8,856,015. Filing ↗machine: r2 · c24 · span 944385–944394 |
| 72 | Amneal Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0001308179-26-000143 | CEO total compensation as printed in Amneal Pharmaceuticals Inc.'s own proxy. As printed: 8,691,745. Filing ↗machine: r4 · c16 · span 470587–470596 |
| 73 | Amphastar Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-13 | 0001297184-26-000023 | CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. Filing ↗machine: span 722923–722932 |
| 74 | ACADIA Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗ |
| 75 | Dynavax Technologies Corporation, Section 10b CEO total | DEF 14A | 2025-04-17 | 0000930413-25-001273 | CEO total compensation as printed in Dynavax Technologies Corporation's own proxy. As printed: 8,210,775. Filing ↗ |
| 76 | Alkermes plc, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001193125-26-143977 | CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267 |
| 77 | Vir Biotechnology, Inc., Section 10b CEO total | DEF 14A | 2026-04-16 | 0001628280-26-025379 | CEO total compensation as printed in Vir Biotechnology, Inc.'s own proxy. As printed: 7,834,045. Filing ↗machine: t71 · r3 · c22 · span 625913–625922 |
| 78 | Organogenesis Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197357 | CEO total compensation as printed in Organogenesis Holdings, Inc.'s own proxy. As printed: 6,811,754. Filing ↗machine: r2 · c31 · span 316005–316014 |
| 79 | Arvinas, Inc, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028156 | CEO total compensation as printed in Arvinas, Inc's own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930 |
| 80 | Bicycle, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001104659-26-046806 | CEO total compensation as printed in Bicycle's own proxy. As printed: 6,341,473. Filing ↗machine: t83 · r5 · c14 · span 491024–491033 |
| 81 | Beam Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-161512 | CEO total compensation as printed in Beam Therapeutics Inc.'s own proxy. As printed: 5,818,525. Filing ↗machine: r2 · c29 · span 502169–502178 |
| 82 | Emergent BioSolutions Inc., Section 10b CEO total | DEF 14A | 2026-03-20 | 0001367644-26-000033 | CEO total compensation as printed in Emergent BioSolutions Inc.'s own proxy. As printed: 5,321,147. Filing ↗machine: t155 · r3 · c15 · span 906918–906927 |
| 83 | Intellia Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197283 | CEO total compensation as printed in Intellia Therapeutics, Inc.'s own proxy. As printed: 5,063,899. Filing ↗machine: r2 · c25 · span 749290–749299 |
| 84 | Denali Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001714899-26-000054 | CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614 |
| 85 | Sana Biotechnology, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174883 | CEO total compensation as printed in Sana Biotechnology, Inc.'s own proxy. As printed: 2,903,010. Filing ↗machine: t69 · r3 · c27 · span 235773–235782 |
| 86 | Section 10a, Ultragenyx Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 87 | Section 10a, Intellia Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-197283 | Intellia Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 88 | Section 10a, Denali Therapeutics Inc. reciprocity | DEF 14A | — | 0001714899-26-000054 | Denali Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 89 | Section 10a, Emergent BioSolutions Inc. reciprocity | DEF 14A | — | 0001367644-26-000033 | Emergent BioSolutions Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 90 | Section 10a, BioCryst Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-026822 | BioCryst Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 91 | Section 10a, Pacira BioSciences, Inc. reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira BioSciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 92 | Section 10a, Halozyme Therapeutics, Inc. reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 93 | Section 10a, Organogenesis Holdings, Inc. reciprocity | DEF 14A | — | 0001193125-26-197357 | Organogenesis Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 94 | Section 10a, Beam Therapeutics Inc. reciprocity | DEF 14A | — | 0001193125-26-161512 | Beam Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 95 | Section 10a, Crinetics Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001658247-26-000030 | Crinetics Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 96 | Section 10a, ANI Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001023024-26-000039 | ANI Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 97 | Section 10a, Vir Biotechnology, Inc. reciprocity | DEF 14A | — | 0001628280-26-025379 | Vir Biotechnology, Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 98 | Section 10a, Supernus Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001104659-26-053111 | Supernus Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 99 | Section 10a, Dynavax Technologies Corporation reciprocity | DEF 14A | — | 0000930413-25-001273 | Dynavax Technologies Corporation names Novavax in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 100 | Section 10a, ACADIA Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 101 | Section 10a, Arvinas, Inc reciprocity | DEF 14A | — | 0001628280-26-028156 | Arvinas, Inc's most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 102 | Section 10a, Amphastar Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001297184-26-000023 | Amphastar Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 103 | Section 10a, Bicycle reciprocity | DEF 14A | — | 0001558370-25-005258 | Bicycle's most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 104 | Section 10a, Insmed Incorporated reciprocity | DEF 14A | — | 0001104506-26-000022 | Insmed Incorporated's most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.